| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63323-0104-06 | 63323-0104 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Sep 9, 2022 | In Use | |
| 67184-0531-03 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb 13, 2023 | In Use | |
| 73207-0304-40 | 73207-0304 | Vimseltinib | ROMVIMZA | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
| 25021-0222-04 | 25021-0222 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 1, 2013 | Mar 31, 2017 | No Longer Used |
| 51672-4063-01 | 51672-4063 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Nov 5, 2003 | In Use | |
| 66758-0950-04 | 66758-0950 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 22, 2015 | In Use | |
| 59148-0070-91 | 59148-0070 | Busulfan | Busulfex | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb 4, 1999 | In Use | |
| 00054-4129-25 | 00054-4129 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Aug 17, 1999 | Jul 11, 2016 | No Longer Used |
| 59572-0710-30 | 59572-0710 | Enasidenib mesylate | Idhifa | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug 1, 2017 | In Use | |
| 73116-0225-28 | 73116-0225 | Duvelisib | COPIKTRA | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 72819-0186-03 | 72819-0186 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 1, 2022 | In Use | |
| 72730-0101-01 | 72730-0101 | infigratinib | TRUSELTIQ | 125.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 72819-0154-04 | 72819-0154 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Apr 25, 2022 | In Use | |
| 62756-0102-60 | 62756-0102 | gemcitabine | INFUGEM | 10.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct 1, 2018 | Jul 31, 2023 | No Longer Used |
| 16571-0816-41 | 16571-0816 | Temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
| 72694-0728-40 | 72694-0728 | Vorasidenib | VORANIGO | 40.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
| 68083-0292-01 | 68083-0292 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan 5, 2018 | In Use | |
| 00338-3991-01 | 00338-3991 | ifosfamide | Ifex | 1.0 g/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec 30, 1988 | In Use | |
| 72611-0779-02 | 72611-0779 | Melphalan hydrochloride | Melphalan hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov 1, 2020 | In Use | ||
| 72694-0879-10 | 72694-0879 | Vorasidenib | VORANIGO | 10.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
| 73594-0101-01 | 73594-0101 | Trilaciclib | COSELA | 300.0 mg/20mL | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Intravenous | Aug 25, 2025 | In Use | |
| 72606-0555-01 | 72606-0555 | Capecitabine | Capecitabine 500mg | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 6, 2019 | In Use | |
| 72606-0557-01 | 72606-0557 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 6, 2019 | In Use | |
| 59923-0713-05 | 59923-0713 | temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
| 51991-0892-33 | 51991-0892 | Erlotinib Hydrochloride | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 5, 2019 | Jul 31, 2025 | No Longer Used |
Found 12250 results — Export these results
Home